Expression of vascular endothelial growth factor in eyes with Coats' disease.

PURPOSE To examine the expression of vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR)-2 in enucleated eyes with Coats' disease. METHODS Formalin-fixed, paraffin-embedded tissue sections from nine globes with Coats' disease were submitted for hematoxylin and eosin staining and immunohistochemistry with anti-VEGF and VEGFR antibodies. RESULTS Histologically, the enucleated eyes demonstrated the presence of macrophage infiltration and cholesterol clefts in the subretinal space. There were marked retinal vascular abnormalities, including dilated vessels with hyalinized vessel walls in six globes. Exudative retinal detachment was noted in all globes. VEGF immunoreactivity was observed in macrophages infiltrating the subretinal space, and in the detached retina including several blood vessels. VEGF-positivity in macrophages was significantly higher in cases containing retinal vessel abnormalities than those without the abnormalities (P < 0.01). VEGFR-2 immunoreactivity was detected in endothelial cells lining the abnormal retinal vessels, where VEGFR-1 or VEGFR-3 was not expressed. CONCLUSIONS Immunoreactivity for VEGF and VEGFR-2 was detected in macrophages and endothelia of abnormal vessels in eyes with Coats' disease. These results suggest that anti-VEGF approach is a promising therapy for patients with Coats' disease.

[1]  S. Kase,et al.  Expression of vascular endothelial growth factor C in human pterygium , 2013, Histochemistry and Cell Biology.

[2]  E. Mackow,et al.  VEGFR2 and Src Kinase Inhibitors Suppress Andes Virus-Induced Endothelial Cell Permeability , 2010, Journal of Virology.

[3]  G. Abecasis,et al.  Age-related macular degeneration-associated variants at chromosome 10q26 do not significantly alter ARMS2 and HTRA1 transcript levels in the human retina , 2010, Molecular vision.

[4]  Hao Wang,et al.  Elevated vascular endothelial growth factor level in Coats’ disease and possible therapeutic role of bevacizumab , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.

[5]  G. A. Limb,et al.  Triamcinolone attenuates macrophage/microglia accumulation associated with NMDA-induced RGC death and facilitates survival of Müller stem cell grafts. , 2010, Experimental eye research.

[6]  Kwang-soo Kim,et al.  Resolution of Severe Macular Edema in Adult Coats' Disease with Intravitreal Triamcinolone and Bevacizumab Injection , 2008, Korean journal of ophthalmology : KJO.

[7]  M. Çakır,et al.  Combined intravitreal bevacizumab and triamcinolone injection in a child with Coats disease. , 2008, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.

[8]  A. Liem,et al.  Balance of Vascular Endothelial Growth Factor and Pigment Epithelial Growth Factor prior to Development of Proliferative Vitreoretinopathy , 2007, Ophthalmic Research.

[9]  Atul K. Jain,et al.  Elevated vascular endothelial growth factor levels in Coats disease: rapid response to pegaptanib sodium , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.

[10]  J. Huot,et al.  Phosphorylation of Tyr1214 within VEGFR-2 Triggers the Recruitment of Nck and Activation of Fyn Leading to SAPK2/p38 Activation and Endothelial Cell Migration in Response to VEGF* , 2006, Journal of Biological Chemistry.

[11]  R. Nussenblatt,et al.  Immunopathologic features of inflammatory coats disease. , 2005, Archives of ophthalmology.

[12]  J. Ambati,et al.  Macrophage depletion inhibits experimental choroidal neovascularization. , 2003, Investigative ophthalmology & visual science.

[13]  C. Shields,et al.  Classification and management of Coats disease: the 2000 Proctor Lecture. , 2001, American journal of ophthalmology.

[14]  R. Gupta,et al.  Cytodiagnosis of Coats' disease from an ocular aspirate. A case report. , 1993, Acta cytologica.